Homepage Featured News
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced preliminary, unaudited results for the year ended December 31, 2022.
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test.
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90%
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers, co-occurring mutations and molecular response to therapy
Guardant Health Reports Third Quarter 2022 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2022.
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
Agreement will leverage GuardantINFORM real-world evidence platform to advance development efforts for core cancer indications